Durvalumab,Tremelimumab

DRUG2 trials

Sponsors

Seoul National University Hospital

Conditions

HNSCCHead and Neck Neoplasms

Phase 2

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

CompletedNCT03292250

Seoul National University HospitalHead and Neck Neoplasms, HNSCC

Start: 2017-09-10End: 2022-03-10Updated: 2022-03-29

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

CompletedNCT06446570

Seoul National University HospitalHead and Neck Neoplasms, HNSCC

Start: 2017-09-10End: 2021-06-03Updated: 2024-06-06

Related Papers

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.

2024-03-072 citations

Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma

Cancers2020-07-0312 citations

Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma.

Journal of Clinical Oncology2018-05-201 citations

Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma.

Journal of Clinical Oncology2018-05-20